ArticleNature medicine2026
Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade.
Abstract read
In one paragraph
Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.Cancer cell · 2026Article
- 25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap.Cancers · 2026Review
- Protocol for selective in vivo labeling of bone marrow plasma cells by intrafemoral antibody injection in mice.STAR protocols · 2026Article
- Immunotherapy-Based Conversion to Curative-Intent Treatment in Hepatocellular Carcinoma: A Multidisciplinary Framework.Cancers · 2026Review
- Immunoglobulin GM (γ marker) allotypes expressed on IgG1 as potential genetic markers of response to immune checkpoint blockade therapy.Journal for immunotherapy of cancer · 2026Article
- Proteome-wide serology reveals immune-defined subtypes of gastrointestinal disease in systemic sclerosis.bioRxiv : the preprint server for biology · 2026Article
- Endogenous neoantigen-specific antibodies mediate antitumor responses and determine vaccine efficacy.Journal for immunotherapy of cancer · 2026Article
- Therapeutic Cancer Vaccines in Gastrointestinal Malignancies: Advances, Challenges, and Emerging Strategies.Cancers · 2026Review
- Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade.Nature medicine · 2026Article
- Identification, design, andFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
62 authors.
Edgar Gonzalez-Kozlova *Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Robert Sweeney *Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Igor Figueiredo *Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Kevin Tuballes *Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-5899-7080
Sinem OzbeyDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-5636-4709
Pauline HamonDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-6776-1635
Matthew D ParkDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Giorgio IoannouDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-7956-7605
Yohei NoseDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-1973-9035
Ruiwei GuoDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-6978-8735
Paula RestrepoDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-2045-2357
Mark BuckupDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-6938-3474
Vladimir RoudkoDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Clotilde HennequinDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-9874-2704
Jessica Le BerichelDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nicholas VenturiniDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-3769-5956
Laszlo HalaszDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-4726-7012
Leanna TroncosoDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-2529-9267
Alexandra TabachnikovaDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Christie ChangDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-7651-7220
Amanda ReidDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0009-0009-3959-0945
Haley BrownDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Theodore ChinDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Rafael CabalDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Raphaël MattiuzDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-3292-1635
Shingo EikawaDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Diane Marie Del ValleDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-6983-5362
Tina Ruth GonsalvesDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nelson M LaMarcheDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Hajra JamalDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Alona LanskyDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nancy YiDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Daniella NelsonDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jarod Morgenroth-RebinDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Raphael MerandDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Bryan VillagomezDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0009-0008-6866-7502
Darwin D'SouzaDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Emir RadkevichDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Kai NieDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Zhihong ChenDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-7403-7015
Yasuko TadaDivision of Cancer Immunology, Research Institute EPOC, National Cancer Center, Tokyo and Chiba, Japan.ORCID http://orcid.org/0000-0001-6033-9856
Hiroyoshi NishikawaDivision of Cancer Immunology, Research Institute EPOC, National Cancer Center, Tokyo and Chiba, Japan.ORCID http://orcid.org/0000-0001-6563-9807
Stephen C WardDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Maria Isabel FielDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Rachel BrodyDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Parissa TabrizianDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ganesh GunasekaranDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Alice O KamphorstDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-9230-9501
Noah CohenDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Maria Curotto de LafailleDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-8883-6368
Olivia HapanowiczDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Natalie LucasDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Kathy WuDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nicola JamesRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.ORCID http://orcid.org/0009-0003-5610-6349
John C LinRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Gavin ThurstonRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Myron SchwartzDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-9113-886X
Nathalie FiaschiRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Seunghee Kim-SchulzeDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-0192-4400
Miriam MeradDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-4481-7827
Thomas U MarronDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-5903-8191
Sacha GnjaticDepartment of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA. sacha.gnjatic@mssm.edu.ORCID http://orcid.org/0000-0001-5643-9520
Funding
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4MHigh-Dimensional Immune Monitoring of NCI-Supported Immunotherapy TrialsU24CA224319 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Sacha Gnjatic, Seunghee Kim-Schulze · 2017 to 2026
$21.5MERK control of Dendritic Cell Differentiation, Homeostasis and DiseaseR01CA154947 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CARL E ALLEN, MIRIAM MERAD · 2011 to 2026
$7.0MInvestigating Macrophage Molecular and Functional Diversity in Tumor ImmunityR01CA254104 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BROWN, BRIAN D, MERAD, MIRIAM · 2021 to 2025
$3.4MDissecting the pathways driving progenitor to pro-tumor macrophage programmingR01CA257195 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Brian D Brown, MIRIAM MERAD · 2021 to 2026
$3.3MCharacterizing and predicting colitis in immune checkpoint blockade-treated cancer patientsU01DK124165 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI COLOMBEL, JEAN-FREDERIC, FAITH, JEREMIAH JAMES · 2020 to 2024
$2.9MType 2 immunity: a primitive response to epithelial injury that shapes bone marrow and lung myeloid crosstalkR01CA277479 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MIRIAM MERAD, Thomas Urban Marron · 2023 to 2026
$2.6MFoundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) CA224319NCI NIH HHS P30 CA196521NCI NIH HHS R01 CA154947NCI NIH HHS R01 CA254104NCI NIH HHS R01 CA257195NCI NIH HHS R01 CA277479NCI NIH HHS U24 CA224319NIDDK NIH HHS U01 DK124165
Abstract
Tumor-infiltrating T cells have been the primary focus of cancer immunotherapy; however, accumulating evidence points to a critical role for B cells and plasma cells in shaping responses to immune checkpoint blockade. In this study, we investigated the humoral immune response in 38 patients with hepatocellular carcinoma treated with neoadjuvant anti-programmed cell death protein 1 (PD-1) therapy. In responders, defined by more than 50% tumor necrosis, we observed on-treatment enrichment of clonally expanded IgG1
Indexed as
Antigens, NeoplasmCarcinoma, HepatocellularImmune Checkpoint InhibitorsImmunity, HumoralImmunoglobulin GLiver NeoplasmsB-LymphocytesFemaleHumansImmunotherapyLymphocytes, Tumor-InfiltratingMaleMembrane ProteinsMiddle AgedPlasma CellsProgrammed Cell Death 1 ReceptorAntigens, NeoplasmCTAG1B protein, humanImmune Checkpoint InhibitorsImmunoglobulin GMembrane ProteinsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorVascular Endothelial Growth Factor A
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.